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A B S T R A C T
Background
Bronchiectasis is a chronic airway disease characterised by a destructive cycle of recurrent airway infection, inflammation and tissue
damage. Antibiotics are a main treatment for bronchiectasis. The aim of continuous therapy with prophylactic antibiotics is to suppress
bacterial load, but bacteria may become resistant to the antibiotic, leading to a loss of effectiveness. On the other hand, intermittent
prophylactic antibiotics, given over a predefined duration and interval, may reduce antibiotic selection pressure and reduce or prevent
the development of resistance. This systematic review aimed to evaluate the current evidence for studies comparing continuous versus
intermittent administration of antibiotic treatment in bronchiectasis in terms of clinical efficacy, the emergence of resistance and serious
adverse events.
Objectives
To evaluate the effectiveness of continuous versus intermittent antibiotics in the treatment of adults and children with bronchiectasis,
using the primary outcomes of exacerbations, antibiotic resistance and serious adverse events.
Search methods
On1August 2017 and 4May 2018 we searched theCochrane Airways Review Group Specialised Register (CAGR), CENTRAL,MED-
LINE, Embase, PsycINFO, CINAHL, and AMED. On 25 September 2017 and 4 May 2018 we also searched www.clinicaltrials.gov,
the World Health Organization (WHO) trials portal, conference proceedings and the reference lists of existing systematic reviews.
Selection criteria
We planned to include randomised controlled trials (RCTs) of adults or children with bronchiectasis that compared continuous versus
intermittent administration of long-term prophylactic antibiotics of at least three months’ duration. We considered eligible studies
reported as full-text articles, as abstracts only and unpublished data.
Data collection and analysis
Two review authors independently screened the search results and full-text reports.
Main results
We identified 268 unique records. Of these we retrieved and examined 126 full-text reports, representing 114 studies, but none of these
studies met our inclusion criteria.
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Authors’ conclusions
No randomised controlled trials have compared the effectiveness and risks of continuous antibiotic therapy versus intermittent antibiotic
therapy for bronchiectasis. High-quality clinical trials are needed to establish which of these interventions is more effective for reducing
the frequency and duration of exacerbations, antibiotic resistance and the occurrence of serious adverse events.
P L A I N L A N G U A G E S U M M A R Y
Are antibiotics more effective when given continuously or intermittently to people with bronchiectasis?
Background
Bronchiectasis is an incurable lung disease characterised by repeated chest infections. Antibiotics are a main form of treatment and can
be taken long term to prevent chest infections from developing. This could be continuously or intermittently for a fixed period of time.
However, we do not currently know which approach is the most effective for reducing the frequency and duration of exacerbations,
managing antibiotic resistance and minimising side effects.
Study Characteristics
On 1 August 2017 we searched a wide range of sources to find clinical trials for our review. We found 268 potentially relevant results
but on closer examination none of the studies met our review criteria and none could be included.
Authors’ conclusions
There is no high-quality evidence about whether continuously administered or intermittently administered antibiotics are safer and
more helpful for people with bronchiectasis. More research is needed to evaluate which one of these methods is better for reducing
chest infections, limiting resistance to antibiotic therapy and reducing serious side effects.
B A C K G R O U N D
Description of the condition
Bronchiectasis is a chronic airway disease characterised by abnor-
mal destruction and dilation of the large airways, bronchi and
bronchioles (Pasteur 2010). It is characterised radiologically by
permanent dilation of the bronchi, and clinically by a syndrome
of cough, sputum production and recurrent respiratory infections
(Chalmers 2014). The pathogenesis of bronchiectasis can be ex-
plained by the vicious cycle theory, whereby an initial insult to the
airway leads to bronchial wall inflammation and damage, and dis-
orderedmucociliary clearance, predisposing the patient to chronic
or recurrent infection resulting in further airway damage (Cole
1986; Chalmers 2013). An understanding of this cycle of persis-
tent bacterial colonisation, chronic inflammation of the bronchial
mucosa, and progressive tissue destruction is central to the man-
agement of bronchiectasis as strategies to arrest both inflamma-
tory and bacterial components are required to limit the progres-
sion of lung injury (Cole 1997; Pasteur 2010). Bacteria most com-
monly isolated from the airways of patients with bronchiectasis
include non-typeableHaemophilus influenzae, Pseudomonas aerugi-
nosa,Streptococcus pneumoniae,Staphylococcus aureus andMoraxella
catarrhalis (Foweraker 2011). Colonising pathogens such as P
aeruginosa,H influenzae and M catarrhalis also commonly display
antimicrobial resistance arising from intrinsic resistance mecha-
nisms or frequent exposure to antimicrobial agents.
Approximately half of presenting cases are classified as idio-
pathic. The most commonly assigned aetiology is post-infec-
tious bronchiectasis, a heterogenous group including patients with
childhood respiratory infections like pertussis, bacterial pneumo-
nia or tuberculosis (Pasteur 2010). Diagnosis is based on identi-
fication of one or more abnormally dilated bronchi using high-
resolution computed tomography (HRCT) (Chang 2010; Pasteur
2010). The main aims of therapeutic management are reduction
of symptoms such as cough, breathlessness and expectoration, re-
duction of the number and duration of exacerbations and im-
provement in quality of life (Pasteur 2010; Chalmers 2015).
Bronchiectasis was once considered a relatively rare disease but
recent studies have suggested increasing prevalence, particularly
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in women and those aged over 60 years (Weycker 2005; Roberts
2010; Seitz 2010), and higher prevalence rates in low- and mid-
dle-income countries (Habesoglu 2011). Prevalence in Germany
in 2013 was estimated at 67 cases per 100,000 general popula-
tion (Ringshausen 2015). In the UK, point prevalence rates per
100,000 rose from 350.5 to 566.1 in women and from 301.2 to
485.5 in men over a nine-year period, reflecting an increase of
more than 60% and approximately 263,000 adults living with
bronchiectasis in 2013 (Quint 2016). Similarly, incidence rates
per 100,000 person-years over the same period rose from 21.2 to
35.2 in women and from 18.2 to 26.9 in men, a 63% increase,
with over 15,000 new cases in 2013. Average European mortal-
ity rates per 100,000 general population are estimated at 0.3 in
27 of the 28 EU countries and at 0.2 in nine non-EU countries,
based on 2005 to 2009 data (European Lung White Book 2013).
Recent UK age-adjusted mortality rates are 2.26 times higher in
women and 2.14 times higher in men compared with the general
population (Quint 2016).
The disease has a significant impact on children, with worse qual-
ity of life in younger children and those with more frequent exac-
erbations (Kapur 2012). Bronchiectasis is also more common in
some indigenous groups where prevalence may be as high as 16
per 1000 among southwest Alaskan children and 15 per 1000 in
Australian Aboriginal and Torres Strait Islander children (Chang
2002). Furthermore, one study reported an incidence of 3.7 per
100,000 per year among New Zealand children aged under 15
years. This equates to an overall prevalence of 1 per 3000 children
and 1 per 625 Pacific children (Twiss 2005). It also demonstrates
that the incidence rate among children in New Zealand is almost
seven times higher than those from Finland (Twiss 2005).
An improvement in diagnosis resulting from easier access to high-
quality CT scanners, and increased awareness of symptoms com-
mon to bronchiectasis and other lung diseases, have been cited as
factors contributing to increased prevalence (Goeminne 2016).
Bronchiectasis places an increasing burden on healthcare systems
internationally (Chalmers 2015; Redondo 2016), with patients
experiencing a high rate of exacerbations, hospital admissions and
attributable mortality (Chalmers 2015). Data from the European
bronchiectasis registry show that approximately half of bronchiec-
tasis patients have two or more exacerbations per year and a third
are hospitalised at least once a year (Polverino 2017). Patients
colonised with P aeruginosa and those with a more frequent an-
nual exacerbation rate have an accelerated decline in lung func-
tion, reduced health-related quality of life (measured using the
St George’s Respiratory Questionnaire, SGRQ), increased risk of
hospitalisation and increased mortality risk (Evans 1996; Wilson
1997; Martínez-García 2007, Polverino 2017). A history of ex-
acerbations, and particularly severe exacerbations, low body mass
index, chronic bacterial infection, low forced expiratory volume
in one second (FEV ) per cent of predicted, a higher propor-
tion of affected lobes and more breathlessness are also associated
with an increased risk of hospitalisation andmortality (Seitz 2010;
Chalmers 2014; Rogers 2014).
This is particularly the case with P aeruginosa infection. A sys-
tematic review of observational studies identified that P aeruginosa
infection is associated with a three-fold increase in mortality risk,
an almost seven-fold increase in risk of hospital admission and an
average of one additional exacerbation per patient per year.
Bronchiectasis care is associated with substantial resource use. A
recent Spanish study reported a mean direct annual medical cost
for adult patients with bronchiectasis of EUR 4671, escalating
with disease severity (de la Rosa 2016). Furthermore, factors such
as FEV percentage predicted, age,Pseudomonas colonisation and
hospitalisation may independently influence health care costs. A
USA-based study reported an annual increase of USD 2319 in
overall costs and USD 1607 in respiratory-related costs in pa-
tients with bronchiectasis compared with matched case-controls,
attributed primarily to an increase of two outpatient visits and 1.6
respiratory-related visits per patient per year (Joish 2013).
Description of the intervention
Antibiotics aiming to treat bacterial infections of the respiratory
tract, or to control bacterial colonisation, or both, represent a cen-
tral component of the treatment of bronchiectasis, as they reduce
bacterial load, inflammation and consequent tissue destruction in
the airways (Chalmers 2012). Long-term prophylactic antibiotics,
administered for more than three months, have proved effective
for patients with frequent bronchiectasis exacerbations or those
with fewer exacerbations causing significant morbidity, as they ap-
pear to decrease the frequency and severity of exacerbations, at
the expense of a significant increase in the risk of emerging drug
resistance (Hnin 2015). Patients taking continuous antibiotics are
more than three times at risk of bacterial resistance compared to
those who do not (Hnin 2015). Pathogens isolated in the spu-
tum cultures of these patients during an exacerbation or at stable
disease, such as P aeruginosa, H influenzae or M catarrhalis, com-
monly display antimicrobial resistance arising from intrinsic resis-
tance mechanisms or frequent exposure to antimicrobial agents.
There is also risk of antibiotic-related adverse effects, such as hear-
ing impairment and cardiotoxicity (Serisier 2013).
Randomised controlled trials (RCTs) have evaluated different
modes of administration, namely oral, intravenous and inhaled,
and different classes of antibiotics including but not limited to
macrolides, quinolones or polymyxins. Two strategies for the ad-
ministration of long-term antibiotics have been described: (I) con-
tinuous and (ii) intermittent administration. In contrast to con-
tinuous, intermittent refers to the repeated prophylactic admin-
istration of courses of antibiotics with predefined duration and
intervals. Examples include one short course of antibiotics every
month; month on and month off; or during the winter months.
We intended this review to include intermittent antibiotic ther-
3Continuous versus intermittent antibiotics for bronchiectasis (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
apy where administration is at predefined regular intervals over a
duration of at least three weeks, and where patients are not receiv-
ing concomitant prophylactic antibiotics. We intended to com-
pare continuous versus intermittent administration of long-term
prophylactic antibiotics for at least three months.
How the intervention might work
There is a strong relationship between airway bacterial infection
and disease morbidity in bronchiectasis; for example, patients
chronically infected with P aeruginosa have a three-fold increase
in mortality, a 6.5 times increase in hospital admission rate and an
average of one additional exacerbation per patient per year, when
compared to patients not chronically infected with P aeruginosa
(Finch 2015). Other commonly isolated bacteria such as H in-
fluenzae and M catarrhalis also drive an increase in neutrophilic
inflammation (Chalmers 2012); and they are associated with an
increased risk of severe exacerbations (Chalmers 2014). Antibiotic
treatment aims to suppress neutrophilic inflammation, reduce bac-
terial load and thereby improve clinical outcomes (Brodt 2014).
Continuous administration of antibiotic treatment is based on the
assumption that chronic infection cannot be eradicated, and must
therefore be continuously suppressed to prevent a return of bac-
terial load, increased inflammation and a recurrence of symptoms
(Haworth 2014).
The argument against continuous exposure to antibiotics is that it
leads to increased bacterial resistance and consequently treatment
may lose its effectiveness (Chalmers 2015). On the contrary, in-
termittent administration of antibiotics might remove or limit the
antibiotic selection pressure and, consequently, prevent the devel-
opment of resistance, although intermittent antibiotics could also
be less effective. While data are lacking on the impact of intermit-
tent versus continuous administration of antibiotics on the devel-
opment of antibiotic resistance among patients with bronchiecta-
sis, there is some indirect evidence. For example, in a large retro-
spective analysis of mechanically-ventilated patients with nosoco-
mial infections (40% chronic lung disease), an interval of at least
20 days between serial courses of antibiotics was associated with a
24% reduction in development of resistance (Hui 2013).
An additional advantage of intermittent antibiotic administration
is a reduced treatment burden to patients, as continuous adminis-
tration may result in more side effects as a result of higher cumu-
lative exposure of the patient to antibiotics.
Why it is important to do this review
While long-term antibiotic treatments givenboth orally and via in-
halation are part of the standard care for patients with bronchiecta-
sis (Chalmers 2015), there is no agreement on the optimal method
of delivery of antibiotic therapies. It is common practice to ad-
minister both oral and inhaled antibiotics daily (Altenburg 2013;
Haworth 2014), on alternate days (Wong 2012), month on and
month off (Barker 2014), or during the winter months when pa-
tients may experience more exacerbations. International guide-
lines are unable to comment on which method of antibiotic ad-
ministration is most effective or is associated with the lowest rates
of adverse events or antibiotic resistance. A European Respiratory
Society/European Bronchiectasis Network (EMBARC) task force
produced 22 consensus recommendations for future research into
bronchiectasis, including “Studies should evaluate whether cyclic
or continuous administration of long-term antibiotics is superior
both in terms of clinical efficacy and the emergence of resistance”
(Aliberti 2016). As this was determined to be an important clin-
ical question by both patients and physicians, this systematic re-
view was intended to evaluate the current evidence for continu-
ous versus intermittent administration of antibiotic treatment in
bronchiectasis.
O B J E C T I V E S
To evaluate the effectiveness of continuous versus intermittent an-
tibiotics in the treatment of adults and children with bronchiec-
tasis, using the primary outcomes of exacerbations, antibiotic re-
sistance and serious adverse events.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We planned to include randomised controlled trials (RCTs) and
cluster-randomised trials. We also planned to include cross-over
studies, but to only use data from the first pre-cross-over phase to
eliminate potentially irreversible carry-over effects (e.g. antibiotic
resistance).We also planned to include studies reported as full text,
those published as abstract only, and unpublished data.
Types of participants
We planned to include adults and children (< 18 years) diagnosed
with bronchiectasis by bronchography, or computed tomography
who reported daily signs or symptoms, such as cough, sputum
production, or those with recurrent episodes of chest infections.
Studies would have been excluded if participants had received a di-
agnosis of cystic fibrosis (CF) or active allergic bronchopulmonary
aspergillosis. We planned to analyse data on children and adults
separately.
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Types of interventions
We aimed to compare continuous versus intermittent administra-
tion of long-term prophylactic antibiotics of at least three months’
duration. The delivery method was to be the same in all study
groups, e.g. nebulised versus nebulised, in order to isolate the ef-
fect of the antibiotic rather than the delivery device.
We considered intermittent administration of antibiotics, pro-
vided that there were predefined regular intervals of antibiotic ad-
ministration followed by a duration of at least three weeks when
participants did not receive prophylactic antibiotics (e.g. one short
course of antibiotics every month; month on and month off; or
during the winter months). We considered antibiotics delivered
without intervals of no antibiotics for the duration of the study to
be continuous.
Types of outcome measures
Primary outcomes
1. Exacerbations (frequency, proportion with one or more,
duration, time to next exacerbation), defined using study
authors’ criteria.
2. Antibiotic resistance, defined as either the presence of
antibiotic resistance after the administration of antibiotics for at
least three months, or the development of antibiotic resistance
within at least three months of antibiotic administration. We
planned to only evaluate resistance to the antibiotic(s) being
investigated.
3. Serious adverse events.
Secondary outcomes
1. Health-related quality of life using measures validated in a
clinical setting (e.g. SGRQ, Leicester Cough Questionnaire
(LCQ), Quality of Life-Bronchiectasis (QoL-B) questionnaire).
2. Hospital admissions due to exacerbations (frequency,
duration), defined using study authors’ criteria.
3. Mortality (we planned to extract and report whether
mortality is defined as all-cause or bronchiectasis-related in the
individual studies).
4. Sputum volume and colour.
5. Symptoms (cough, dyspnoea, wheeze).
6. Lung function measured as forced expiratory volume in one
second (FEV ) (litres or per cent of predicted).
7. Exercise capacity (e.g. Six-Minute Walk Test or Incremental
Shuttle Walk Test).
8. Adverse events/side effects.
We planned to use the definitions fromEdwards 2000 andHansen
2015 for serious adverse events and adverse events as follows.
1. Serious adverse events are those that result in death or life-
threatening events; requirement for hospitalisation or
prolongation of existing hospitalisation; persistent or significant
disability; or congenital anomalies; or are events considered
medically important.
2. Adverse events are any untoward occurrence that presents
while a patient is taking a drug but does not necessarily have a
causal relation to the treatment. They are undetectable by the
patient; usually identified by laboratory tests (e.g. biochemical,
haematological, immunological, radiological, and pathological
tests); or by clinical investigations (e.g. gastro-intestinal
endoscopy, cardiac catheterisation).
Reporting one or more of the outcomes listed here in the study
was not an inclusion criterion for the review.
Search methods for identification of studies
Electronic searches
We identified studies from the Cochrane Airways Group Register
of Trials, which is maintained by the Information Specialist for
the Group. The Cochrane Airways Trials Register contains studies
identified from several sources, as follows.
1. Monthly searches of the Cochrane Central Register of
Controlled Trials (CENTRAL, in the Cochrane Library),
through the Cochrane Register of Studies Online
(crso.cochrane.org);
2. Weekly searches of MEDLINE Ovid SP 1946 to date;
3. Weekly searches of Embase Ovid SP 1974 to date;
4. Monthly searches of PsycINFO Ovid SP;
5. Monthly searches of CINAHL EBSCO (Cumulative Index
to Nursing and Allied Health Literature);
6. Monthly searches of AMED EBSCO (Allied and
Complementary Medicine); and
7. Handsearches of the proceedings of major respiratory
conferences.
We identified studies contained in the Trials Register through
search strategies based on the scope of the Cochrane Airways
Group. Details of these strategies, as well as a list of handsearched
conference proceedings, are in Appendix 1. See Appendix 2 for
search terms used to identify studies for this review.
We searched the following trials registries.
1. US National Institutes of Health Ongoing Trials Register
ClinicalTrials.gov (www.ClinicalTrials.gov);
2. World Health Organization International Clinical Trials
Registry Platform (apps.who.int/trialsearch).
We searched the Cochrane Airways Trials Register and additional
sources from inception to 1 August 2017 and registries on 25
September 2017, with no restriction on language of publication.
Searching other resources
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We checked the reference lists of all primary studies and review
articles for additional references. We searched relevant manufac-
turers’ websites for study information.
Weplanned to search for errata or retractions from included studies
published in full text on PubMed and to report the date this was
done within the review.
Data collection and analysis
Selection of studies
Two review authors (SM and TD) independently screened the ti-
tles and abstracts of the search results and coded them as ’retrieve’
(eligible or potentially eligible/unclear) or ’do not retrieve’. We
retrieved the full-text study reports of all potentially eligible stud-
ies and two review authors (SM and TD) independently screened
them for inclusion, recording the reasons for exclusion of ineligible
studies. We resolved disagreement through discussion or, if it had
been necessary, we planned to consult a third review author (JC).
We identified and excluded duplicates and collated multiple re-
ports of the same study so that each study, rather than each report,
was the unit of interest in the review. We recorded the selection
process in sufficient detail to complete a PRISMA flow diagram
and ’Characteristics of excluded studies’ table (Moher 2009).
Data extraction and management
We planned to use a data collection form for study characteristics
and outcome data, that had been piloted on at least one study
in the review. One review author (TD) would have extracted the
following study characteristics from included studies.
1. Methods: study design, total duration of study, details of
any ’run-in’ period, number of study centres and location, study
setting, withdrawals and date of study.
2. Participants: N, mean age, age range, gender, severity of
condition, diagnostic criteria, baseline lung function, smoking
history, inclusion criteria and exclusion criteria.
3. Interventions: intervention, comparison, concomitant
medications and excluded medications.
4. Outcomes: primary and secondary outcomes specified and
collected, and time points reported.
5. Notes: funding for studies and notable conflicts of interest
of trial authors.
We planned for two review authors (TD and LF) to independently
extract outcome data from included studies. We planned to note
in the ’Characteristics of included studies’ table where outcome
data were not reported in a usable way. We planned to resolve
disagreements by consensus or by involving a third review author
(JC). We also planned for one review author (TD) to transfer data
into the Review Manager 5 file (Review Manager 2014); and to
double-check that data were entered correctly by comparing the
systematic review with the study reports. We planned for a second
review author (LF) to spot-check study characteristics for accuracy
against the study report.
Assessment of risk of bias in included studies
Weplanned for two review authors (LF and TD) to independently
assess risk of bias for each study using the criteria outlined in
the Cochrane Handbook for Systematic Reviews of Interventions (
Higgins 2011); and to resolve disagreements by discussion or by
involving another author (SM). We planned to assess the risk of
bias according to the following domains.
1. Random sequence generation.
2. Allocation concealment.
3. Blinding of participants and personnel.
4. Blinding of outcome assessment.
5. Incomplete outcome data.
6. Selective outcome reporting.
7. Other bias.
We planned to judge each potential source of bias as high, low or
unclear and provide a quote from the study report together with a
justification for our judgement in the ’Risk of bias’ table. We also
planned to summarise the risk of bias judgements across different
studies for each of the domains listed. We planned to consider
blinding separately for different key outcomes where necessary
(e.g. for unblinded outcome assessment, risk of bias for all-cause
mortality may be very different than for a patient-reported pain
scale). Where information on risk of bias related to unpublished
data or correspondence with a trialist, we planned to note this in
the ’Risk of bias’ table.
When considering treatment effects, we planned to take into ac-
count the risk of bias for the studies that contributed to that out-
come.
Assessment of bias in conducting the systematic
review
We conducted the review according to the published protocol
and planned to justify any deviations from it in the ’Differences
between protocol and review’ section of the systematic review.
Measures of treatment effect
We planned to analyse dichotomous data as odds ratios, and con-
tinuous data as mean differences or standardised mean differences.
We planned to enter data presented as a scale with a consistent
direction of effect.
We planned to undertake meta-analyses only when it was mean-
ingful (i.e. when treatments, participants and the underlying clin-
ical question were similar enough for pooling to make sense).
We planned to narratively describe skewed data reported as medi-
ans and interquartile ranges.
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Ifmultiple trial arms had been reported in a single trial, we planned
to include only the relevant arms. If two comparisons (e.g. drug
A versus placebo and drug B versus placebo) had been combined
in the same meta-analysis, we planned to halve the control group
to avoid double-counting.
Unit of analysis issues
If we had included any studies, the unit of analysiswould have been
the participant. In terms of exacerbation rates and hospitalisation
rates, we planned to focus on the number of events experienced
by the participant during the trial and to analyse the results using
rate ratios if possible. We planned to use adjusted data where it
was available (e.g. rate ratios from Poisson regression models, or
mean differences fromANOVAor results from cluster randomised
studies adjusted for cluster effect) as a first choice, followed by
change scores and final scores as last choice.
Dealing with missing data
We planned to contact investigators or study sponsors in order to
verify key study characteristics and to obtain missing numerical
outcome datawhere possible (e.g. when a studywas only identified
as an abstract). Where this was not possible, and missing data were
thought to introduce serious bias, we planned to take this into
consideration in the GRADE rating for affected outcomes.
Assessment of heterogeneity
We planned to use the I² statistic to measure heterogeneity among
the studies in each analysis; and if we had identified substantial
heterogeneity, to report it and explore possible causes using the
prespecified subgroup analyses.
Assessment of reporting biases
If we had been able to pool more than 10 studies, we would have
created and examined a funnel plot to explore possible small-study
and publication biases.
Data synthesis
We planned to conduct meta-analyses when the population, inter-
ventions, outcomes and study designs were similar. In the presence
of substantial heterogeneity (> 50%), we planned to report out-
comes in the text, giving direction and size of the effect along with
the strength of the evidence (risk of bias). We envisaged that an-
tibiotic studies would vary by population, design, and outcomes,
and therefore meta-analysis using a random-effects model would
be most appropriate. However, where there are few studies or the
effects of interventions across studies are not randomly distributed
(e.g. with publication bias), the estimates from a random-effects
model may be unreliable or biased. It was likely that this review
would only include a small number of low-powered studies, and
we had therefore planned to use a fixed-effect model, reported
with 95% confidence intervals (CI), and to evaluate the impact of
model choice using a sensitivity analysis. We planned to synthe-
sise and report dichotomous and continuous data separately for
each outcome (e.g. exacerbation/no exacerbation or exacerbation
duration). Where end-of-study point estimates and change from
baseline scores were reported, we planned to analyse these sepa-
rately. Furthermore, we planned to use standardised mean differ-
ences (SMD) when outcomes weremeasured using different scales
(e.g. health-related quality of life measures) and to use the baseline
standard deviation (SD) for SMD analyses.
’Summary of findings’ table
We planned to create a ’Summary of findings’ table using the fol-
lowing outcomes: exacerbations; antibiotic resistance; serious ad-
verse events; hospitalisations; mortality; symptoms; and quality
of life. We planned to use the five GRADE considerations (risk
of bias, consistency of effect, imprecision, indirectness and publi-
cation bias) to assess the overall quality of the evidence in terms
of the studies that contributed data to the prespecified outcomes.
We planned to use the methods and recommendations described
in Section 8.5 and Chapter 12 of the Cochrane Handbook for Sys-
tematic Reviews of Interventions (Higgins 2011), using GRADE-
pro software (GRADEpro GDT); and to justify all decisions to
downgrade the quality of studies using footnotes. We planned to
include comments to aid the reader’s understanding of the review
where necessary.
Subgroup analysis and investigation of heterogeneity
We planned to carry out the following subgroup analyses.
1. Mode of delivery (e.g. oral, nebulised).
2. Antibiotic class (e.g. macrolide).
3. Duration participants colonised with P aeruginosa.
4. Specifically for the outcome antibiotic resistance, we
planned subgroup analyses according to the definition of
antibiotic resistance (presence of antibiotic resistance versus
development of antibiotic resistance, following at least three
months’ administration of antibiotics).
We planned to use the following outcomes in subgroup analyses.
1. Exacerbations.
2. Antibiotic resistance.
3. Serious adverse events.
We planned to use the formal test for subgroup interactions in
Review Manager 5 (Review Manager 2014).
Sensitivity analysis
Weplanned to evaluate the impact ofmethodological quality using
the following domains to remove studies at high or unclear risk of
bias.
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1. Random sequence generation.
2. Allocation concealment.
We planned to compare the results from a fixed-effect model with
the random-effects model.
R E S U L T S
Description of studies
Results of the search
We identified 268 study reports in our database searches on 1 Au-
gust and 25 September 2017, and 4 May 2018. We also searched
the USA National Institutes of Health Ongoing Trials Register (
www.ClinicalTrials.gov), theWorld Health Organization Interna-
tional Clinical Trials Registry Platform (apps.who.int/trialsearch),
conference proceedings and the reference lists of existing system-
atic reviews. We identified 13 additional records through other
sources (WHO trials portal) but they were not relevant to our
inclusion criteria Figure 1
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Figure 1. Study flow diagram.
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Included studies
We did not identify any studies relevant to our inclusion criteria.
Excluded studies
One hundred and twenty-six study reports (covering 114 studies)
were excluded, with reasons, from original database searches fol-
lowing inspection of the study report (Characteristics of excluded
studies). Sixty-seven (59%)were not randomised studies (andwere
also otherwise not relevant to our inclusion criteria), 23 (20%)
compared an antibiotic versus placebo, 12 (10%) compared dif-
ferent antibiotics, five (4%) made a comparison between doses of
the same antibiotic, two (2%) were excluded on the basis of the
study having no relevance to the condition. The following were
also excluded: Juqin mixture (Chinese medicine) aerosol inhala-
tion plus standard care versus standard care alone, one (1%); com-
parison between Pidotimod versus no treatment, one (1%); com-
parison between herbal decoction with standard decoction, one
(1%); comparison between colistimethate sodium versus saline so-
lution, one (1%); and the one remaining record (1%) was a letter.
Risk of bias in included studies
No studies met the review inclusion criteria (Criteria for
considering studies for this review). We were therefore unable to
conduct the planned assessment risk of bias.
Effects of interventions
We were unable to evaluate the effectiveness of continuous versus
intermittent antibiotics for bronchiectasis given the absence of
studies meeting our inclusion criteria.
D I S C U S S I O N
Summary of main results
We planned to evaluate the effectiveness of continuous versus in-
termittent antibiotics for bronchiectasis with respect to our pre-
defined outcomes. Despite a comprehensive search, we identi-
fied no randomised trials meeting our predefined inclusion cri-
teria (Criteria for considering studies for this review), revealing a
paucity of evidence in this area.
Overall completeness and applicability of
evidence
We were unable to assess completeness and applicability of evi-
dence as no studies met our inclusion criteria.
Quality of the evidence
Wewere unable to consider the quality of the evidence as no studies
were included in this review.
Potential biases in the review process
We carried out an extensive and comprehensive search for relevant
studies, with expert support from the Cochrane Airways Group.
We conducted searches in nine databases, and obtained translation
of all potentially relevant non-English publications identified in
our searches.
Agreements and disagreements with other
studies or reviews
Althoughnoother relevant systematic reviews or clinical trialswere
identified in our searches, in clinical practice both continuous and
intermittent antibiotic administration is used with competing ra-
tionale (Chalmers 2015). Intermittent antibiotic treatment may
help to limit resistance, because although antibiotics select for re-
sistant bacteria, resistance often carries a ’fitness cost’ for bacteria,
meaning that resistant organisms are then overgrown once antibi-
otics are discontinued (Melnyk 2015). This is the reason that in-
haled antibiotics are often administered in 28-day cycles with 28
days off between cycles. Two trials of aztreonam lysine have been
performed using an intermittent regime in bronchiectasis (Barker
2014), while many antibiotics including tobramycin and aztre-
onam in cystic fibrosis are administered intermittently (Elborn
2016). In a network meta-analysis continuous administration of
inhaled colistin was indirectly compared to intermittent admin-
istration of inhaled tobramycin and aztreonam for patients with
cystic fibrosis and pseudomonas infection. Comparable efficacies
were found between these arms, however their results are limited
by a small overall study population and heterogeneity (Littlewood
2012). Evidence that this approach limits resistance in bronchiec-
tasis is lacking. An added benefit of intermittent administration
for inhaled antibiotics is that inhaled antibiotic therapy can take
a long time to deliver, and so less frequent administration can
improve compliance (McCullough 2014). Some preparations are
also expensive and therefore intermittent administrationmay limit
costs. For oral antibiotic administration, some studies suggest that
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bronchiectasis exacerbations are seasonal; for example Bibby and
colleagues showed that admissions for bronchiectasis were more
frequent in the winter and spring (Bibby 2015). Therefore it is
common practice in some countries to give prophylactic antibi-
otics only during the winter.
Conversely, the argument in favour of continuous administration
of antibiotics is that airway bacterial load, which is suppressed by
antibiotics, rebounds back to baseline levels after approximately
14 days of antibiotic discontinuation, and this provokes increased
airway inflammation (Chalmers 2012; Wilson 2013). Studies of
azithromycin and nebulized gentamicin have shown that treat-
ment benefit is lost once the drug is discontinued, although fol-
low-up in both studies was only three months.(Murray 2011;
Altenburg 2013).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Our review revealed a lack of relevant high-quality evidence, as
thorough systematic searches failed to yield any randomised con-
trolled trials comparing continuous versus intermittent prophy-
lactic antibiotic administration for bronchiectasis.
Due to lack of scientific evidence on the comparative risks and ben-
efits of continuous versus intermittent antibiotics for this popula-
tion, British, European and Spanish guidelines have made recom-
mendations based on the available literature, which at themoment
are the only available guide for the management of patients with
bronchiectasis (Pasteur 2010; Polverino 2017; Martínez-García
2018). For example, the European guidelines recommend long-
term antibiotics for people with three or more exacerbations per
year but make no recommendations regarding a continuous or
intermittent therapeutic regime (Polverino 2017).
Implications for research
Although cystic fibrosis research may provide some insight it is
likely bronchiectasis has different patterns of efficacy and partic-
ularly antibiotic resistance for continuous or intermittent antibi-
otics. They are different clinical entities and a direct extrapolation
of clinical beneficial treatments in cystic fibrosis may not apply to
bronchiectasis (Barker 2014). In identifying the most important
research priorities for bronchiectasis, the European Bronchiecta-
sis Network (EMBARC) reported the following as a key research
question: “Studies should ideally evaluate whether cyclic or con-
tinuous administration of long-term antibiotics is superior both in
terms of clinical efficacy and the emergence of resistance” (Aliberti
2016). This question is important because long-term antibiotic
prophylaxis is widely used, and resolving this question has impor-
tant implications for both efficacy and antibiotic resistance. Our
review identified no studies that could answer this question.
It is evident that there is urgent need for robust randomised trials to
evaluate continuous versus intermittent antibiotics for bronchiec-
tasis with respect to: exacerbations (frequency, proportion with
one or more, duration, time to next exacerbation) ideally defined
using a new international consensus definition (Hill 2017); an-
tibiotic resistance (defined as either the presence of antibiotic re-
sistance after the administration of antibiotics for at least three
months, or the development of antibiotic resistance within at least
three months of antibiotic administration); and serious adverse
events.
Similarly, consideration of the benefits of continuous versus inter-
mittent antibiotics with respect to the following outcomes would
also be especially helpful: health-related quality of life using mea-
sures validated in a clinical setting (e.g. SGRQ, LCQ, QoL-B);
hospital admissions due to exacerbations (both in terms of fre-
quency and duration); mortality; sputum volume and colour;
symptoms (cough, dyspnoea, wheeze); lung function measured as
forced expiratory volume in one second (FEV ); exercise capacity
(e.g. Six-Minute Walk Test); and adverse events/side effects.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Aksamit 2016 Comparison between ciprofloxacin versus placebo
Aksamit 2017 Comparison between ciprofloxacin (intermittent for 28 days) versus ciprofloxacin (intermittent
for 14 days) versus placebo
Al-Mobeireek 1998 Study to determine the range and sensitivity of bacterial pathogens in infective exacerbations of
bronchiectasis
Alberto 1968 Randomised comparison of thiamphenicol glycinate plus acetylcysteine (FZ280E) versus thi-
amphenicol glycinate in chronic bronchopulmonary disease
Alekseenko 1978 Comparison between antibiotics with direct current intervention versus antibiotics alone in the
treatment of inflammatory suppurative diseases of the lungs
Alekseenko 1980 Not a randomised trial. Study focusing on antibiotics and bronchial sanitations
Aliberti 2016 Not a randomised trial. Consensus statement on the management of bronchiectasis
Antoniu 2013 Comparison between ciprofloxacin versus placeb
Cherniack 1959 Not a randomised trial. Comparison among placebo versus tetracycline versus oleandomycin-
penicillin versus penicillin
ChiCTR-IOR-16008910 2016 Comparison between procalcitonin versus control (conventional treatment). Study yet to be com-
pleted in 2017
Chonabayasi 1988 Not a randomised trial. Before and after comparison of T-3262 in respiratory infections
Choo 2018 Comparison between erythromycin versus placebo
Cseri 1975 No indication of randomisation. Comparison between sumetrolim versus oxytetracycline for
chronic non-specific respiratory tract infections
Currie 1987 Comparison between amoxycillin versus placebo
Dimakou 2017 Comparison between tobramycin versus colistin
Douglas 1957 Comparison between chloramphenicol versus oxytetracycline
Hayashi 1989 Not a randomised trial. Evaluation of cefdinir in the treatment of pneumonia
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(Continued)
Hill 1992 Comparison between 200 mg twice daily versus 400 mg twice daily of loracarbef (LY 163892)
Howie 1976 Letter
Huang 2018 Comparison between herbal decoction with standard decoction
Hughes 1973 Comparison between trimethoprim and ampicillin
Iglauer 1973 Comparison between trimethoprim versus sulphamethoxazol
Inoue 1989 Not a randomised trial. Evaluation of 7432-S
Irabu 1989 Not a randomised trial. Evaluation of cefdinir
Irabu 1992 Not a randomised trial. Evaluation of ME1207
Juthong 2011 Comparison between roxithromycin versus placebo
Kanai 1963 Spectrophotometric examination of the respiratory chain
Kawano 1974 Comparison between 200 mg versus 400 mg of amikacin
Kawashima 1989 Not a randomised trial. Observational study of branhamella catarrhalis infection in pulmonary
disorders
Koyama 1992 Not a randomised trial. Evaluation of ME1207
Krawczyk 1981 Not a randomised trial. Evaluation of antibiotics and biceptol preparation
Kudo 1992 Not a randomised trial. Evaluation of ME1207
Kurishima 1992 Not a randomised trial. Evaluation of cefclidin
Kuze 1988 Not a randomised trial. Evaluation of cefodizime (THR-221) in respiratory tract infections
Lamotte 1981 Not a randomised trial. Overview of bronchiectasis
Ledson 2000 Not a randomised trial. N of 1 study of nebulised taurolidine
Lunacharskaia 1968 Evaluation of intratracheal administration of morphocycline
Maekawa 1967 Study did not include participants with bronchiectasis
Masuno 1992 Not a randomised trial. Evaluation of cefclidin
Matsumoto 1984 Not a randomised trial. Evaluation of lenampicillin (KBT-1585) in respiratory infection
Matsumoto 1992 Not a randomised trial. Evaluation of ME1207 in the treatment of respiratory tract infection
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(Continued)
Matsuura 1993 Not a randomised trial. Evaluation of S-1108 in elderly patients
May 1974 Comparison between amoxicillin versus ampicillin
Mazzei 1993 Not a randomised trial. Evaluation of ciprofloxacin for lower respiratory tract infections
Messens 1973 Comparison between sulfamethoxazoletrimethoprim versus demethylchlortetracycline in the treat-
ment of pulmonary infections
Milcev 1985 Focus of this before and after comparison was on anaerobic pulmonary infections and their resis-
tance to antibiotics
Ming 2005 Comparison between macrolide with theophylline versus ’necessary antibiotics’
Molodtsova 1980 Evaluation of penicillin, streptomycin, monomycin, levomycetin zeporin, chemotripcin and gi-
grolitin
Morrone 1989 Participants were randomised to receive 400 mg versus 800 mg of Ofloxacin, two doses per day for
10 days for a total of 400 mg per day or 800 mg per day. Comparison therefore not intermittent
versus continuous
Murayama 1992 Not a randomised trial. Evaluation of ME1207 for respiratory infections
Nagy 1968 Not a randomised trial
Nakagawa 1989 Not a randomised trial. Evaluation of cefdinir in respiratory tract infections
Nakagawa 1993 Not a randomised trial
Nasu 1988 Not a randomised trial. Evaluation of T-3262 in respiratory tract infections
NCT00415350 Comparison between azithromycin versus placebo
NCT00524095 Comparison between fluticasone versus azithromycin (study terminated and did not proceed to
treatment phase
NCT00775138 Comparison between 280 mg versus 560 mg arikace versus placebo
NCT00889967 Comparison between ciprofloxacin versus placebo
NCT00930982 Comparison between ciprofloxacin versus placebo
NCT01313624 Comparison between aztreonam versus placebo
NCT01515007 Comparison between iprofloxacin for Inhalation versus placebo liposomes for inhalation
NCT01538667 Evaluation of lung deposition, pharmacokinetics, safety and tolerability of ciprofloxacin dry powder
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(Continued)
NCT01761214 Not a randomised trial. Evaluation of fluroquinolones
NCT02035488 Not a randomised trial. Evaluation of tobramycin
NCT02047773 Evaluation of bacterial load guided therapy
NCT02081963 Comparison between amikacin and normal saline
NCT02102152 Comparison between tobramycin versus placebo
NCT02104245 Comparison between pulmaquin versus placebo
NCT02107274 Comparison between azithromycin versus placebo
NCT02315547 Not a randomised trial. Comparison between bronchiectasis patients and healthy participants
NCT02491723 Not a randomised trial. Evaluation of azithromycin
NCT02509091 Fundamental treatment combining with the therapy of bronchoalveolar lavage and local amikacin
injection versus fundamental treatment alone
NCT02657473 Comparison between tobramycin inhalation solution and saline inhalation solution
NCT02661438 Not a randomised trial. Evaluation of ciprofloxacin
NCT03058718 Evaluation of procalcitonin-guided antibiotic therapy
NCT03093974 Comparison between colistimethate sodium versus saline solution
NCT03460704 Comparison between colistimethate sodium versus saline Solution
Neumayr 1963 Not a randomised trial
O’Donnell 2016 Comparison of Pulmaquin versus placebo
Obana 1992 Not a randomised controlled trial. Evaluation of ME1207 in respiratory tract infections
Odagiri 1992 Not a randomised controlled trial. Evaluation of ME1207 in respiratory tract infections
Oizumi 1978 Not a randomised controlled trial. Evaluation of amikacin in urinary and respiratory tract infections
Pezza 1983 Not a randomised trial. Evaluation of ceftriaxone in pneumonia with acute exacerbations
Rikitomi 1988 Not a randomised controlled trial. Evaluation of TE-031 (A-56268) in treatment of bacterial
respiratory tract infections
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(Continued)
Saito 1993 Evaluation of the clinical effects of clindamycin on respiratory infections
Santiveri 1995 Evaulation of inhaled antibiotic treatment for pseudomonas aeruginosa
Schulz 1972 Evaluation of chloramphicol and tetrazycline
Serisier 2011 Comparison between DRCFI (a novel liposomal formulation) versus placebo
Serisier 2012 Comparison between erythromycin versus placebo
Shigeno 1984 Not a randomised controlled trial. Evaluation of lenampicillin (KBT-1585)
Shimada 1988 Not a randomised controlled trial. Evaluation of NY-198 in urinary and respiratory tract infections
Shimokata 1992 Not a randomised controlled trial. Evaluation of cefclidin on respiratory tract infections
Shishido 1995 Comparison between 100 mg and 200 mg levofloxacin
Simioli 2017 Comparison between pidotimod 800 mg OD versus no treatment
Soejima 1988 Not a randomised controlled trial. Evaluation of TE-031 (A-56268)
Suga 1988 Not a randomised controlled trial. Evaluation of T-3262 in respiratory tract infection
Sun 2015 Juqin mixture aerosol inhalation + standard care versus standard care alone
Suyama 1988 Not a randomised controlled trial. Evaluation of T-3262 cefodizime (THR-221)
Tagaya 2001 Not a randomised controlled trial. Comparison between clarithromycin versus ammoxicilin
Tamura 1992 Full review of this study not available. However the intervention is not used in clinical practice
Tanimoto 1992 Not a randomised controlled trial. Evaluation ofME 1207 in the treatment of respiratory infections
Tanimoto 1993 Not a randomised controlled trial. Evaluation of S-1108 in the treatment of respiratory infections
Twiss 2009 Comparison between nebulised gentamicin versus placebo
Wada 1992 Not a randomised controlled trial and not participants with bronchiectasis. Respiratory tract in-
fections
Watanabe 1988 Not a randomised controlled trial and not participants with bronchiectasis
Watanabe 1991 Not a randomised controlled trial
Watanabe 1995 Not a randomised controlled trial
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(Continued)
Weston 1966 Not a randomised controlled trial and not participants with bronchiectasis. Chronic bronchitis
Wilson 2011 Comparison with placebo
Wong 2004 Comparison between levofloxacin versus ceftazidime
Yamada 1993 Not a randomised controlled trial and not participants with bronchiectasis
Yoshida 1989 Not a randomised controlled trial and not participants with bronchiectasis
Zegaya 1981 Not a randomised controlled trial. Evaluation of doxycycline in pleuropulmonary affections
Characteristics of ongoing studies [ordered by study ID]
NCT02712983
Trial name or title Dose-finding Study to Assess the Efficacy, Safety and Tolerability of Tobramycin Inhalation Powder in Patients
With Non-Cystic Fibrosis Bronchiectasis and Pulmonary P. Aeruginosa Infection (iBEST-1)
Methods Parallel group randomized trial
Participants Patients with non-cystic fibrosis bronchiectasis and pulmonary P Aeruginosa infection
Interventions tobramycin inhalation powder (TIP) dose and placebo, 3 dose regimens
Outcomes P aeruginosa density in sputum
Starting date 2 February 2017
Contact information Novartis Pharmaceuticals: email: trialandresults.registries@novartis.com
Notes Estimated completion date: 10 September 2018
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A P P E N D I C E S
Appendix 1. Sources and search methods for the Cochrane Airways Group’s Specialised Register
(CAGR)
Electronic searches: core databases
Database Frequency of search
CENTRAL (the Cochrane Library) Monthly
MEDLINE (Ovid) Weekly
Embase (Ovid) Weekly
PsycINFO (Ovid) Monthly
CINAHL (EBSCO) Monthly
AMED (EBSCO) Monthly
Handsearches: core respiratory conference abstracts
Conference Years searched
AmericanAcademyofAllergy, Asthma and Immunology (AAAAI) 2001 onwards
American Thoracic Society (ATS) 2001 onwards
Asia Pacific Society of Respirology (APSR) 2004 onwards
British Thoracic Society Winter Meeting (BTS) 2000 onwards
Chest Meeting 2003 onwards
European Respiratory Society (ERS) 1992, 1994, 2000 onwards
International PrimaryCareRespiratoryGroupCongress (IPCRG) 2002 onwards
Thoracic Society of Australia and New Zealand (TSANZ) 1999 onwards
MEDLINE search strategy used to identify studies for the CAGR
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Condition search
1. exp Asthma/
2. asthma$.mp.
3. (antiasthma$ or anti-asthma$).mp.
4. Respiratory Sounds/
5. wheez$.mp.
6. Bronchial Spasm/
7. bronchospas$.mp.
8. (bronch$ adj3 spasm$).mp.
9. bronchoconstrict$.mp.
10. exp Bronchoconstriction/
11. (bronch$ adj3 constrict$).mp.
12. Bronchial Hyperreactivity/
13. Respiratory Hypersensitivity/
14. ((bronchial$ or respiratory or airway$ or lung$) adj3 (hypersensitiv$ or hyperreactiv$ or allerg$ or insufficiency)).mp.
15. ((dust or mite$) adj3 (allerg$ or hypersensitiv$)).mp.
16. or/1-15
17. exp Aspergillosis, Allergic Bronchopulmonary/
18. lung diseases, fungal/
19. aspergillosis/
20. 18 and 19
21. (bronchopulmonar$ adj3 aspergillosis).mp.
22. 17 or 20 or 21
23. 16 or 22
24. Lung Diseases, Obstructive/
25. exp Pulmonary Disease, Chronic Obstructive/
26. emphysema$.mp.
27. (chronic$ adj3 bronchiti$).mp.
28. (obstruct$ adj3 (pulmonary or lung$ or airway$ or airflow$ or bronch$ or respirat$)).mp.
29. COPD.mp.
30. COAD.mp.
31. COBD.mp.
32. AECB.mp.
33. or/24-32
34. exp Bronchiectasis/
35. bronchiect$.mp.
36. bronchoect$.mp.
37. kartagener$.mp.
38. (ciliary adj3 dyskinesia).mp.
39. (bronchial$ adj3 dilat$).mp.
40. or/34-39
41. exp Sleep Apnea Syndromes/
42. (sleep$ adj3 (apnoea$ or apnoea$)).mp.
43. (hypopnoea$ or hypopnoea$).mp.
44. OSA.mp.
45. SHS.mp.
46. OSAHS.mp.
47. or/41-46
48. Lung Diseases, Interstitial/
49. Pulmonary Fibrosis/
50. Sarcoidosis, Pulmonary/
51. (interstitial$ adj3 (lung$ or disease$ or pneumon$)).mp.
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52. ((pulmonary$ or lung$ or alveoli$) adj3 (fibros$ or fibrot$)).mp.
53. ((pulmonary$ or lung$) adj3 (sarcoid$ or granulom$)).mp.
54. or/48-53
55. 23 or 33 or 40 or 47 or 54
Filter to identify RCTs
1. exp “clinical trial [publication type]”/
2. (randomised or randomised).ab,ti.
3. placebo.ab,ti.
4. dt.fs.
5. randomly.ab,ti.
6. trial.ab,ti.
7. groups.ab,ti.
8. or/1-7
9. Animals/
10. Humans/
11. 9 not (9 and 10)
12. 8 not 11
The MEDLINE strategy and RCT filter are adapted to identify studies in other electronic databases
Appendix 2. Search strategy to identify relevant studies from the CAGR
#1 BRONCH:MISC1
#2 MeSH DESCRIPTOR Bronchiectasis Explode All
#3 bronchiect*
#4 #1 or #2 or #3
#5 MeSH DESCRIPTOR Anti-Bacterial Agents Explode 1
#6 antibiotic* or anti-biotic*
#7 anti-bacteri* or antibacteri*
#8 *cillin
#9 *mycin or micin*
#10 *oxacin
#11 *tetracycline
#12 macrolide*
#13 quinolone*
#14 trimethoprim
#15 ceph*
#16 sulpha*
#17 #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16
#18 #4 and #17
[In search line #1, MISC1 denotes the field in the record where the reference has been coded for condition, in this case, bronchiectasis]
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C O N T R I B U T I O N S O F A U T H O R S
All review authors contributed to the Background section. LF and SS contributed to the Methods section. SM and TD screened the
searches. All authors contributed to results, discussion and conclusions.
D E C L A R A T I O N S O F I N T E R E S T
J Chalmers: part of the EMBARC group that set research priorities in bronchiectasis. He also receives grant support from Pfizer,
AstraZeneca and GlaxoSmithKline. In addition, he is part of an innovative medicines initiative consortium that includes Novartis
and Basilea Pharmaceutica. He has participated in advisory boards for Bayer HealthCare, Chiesi and Raptor Pharmaceuticals. He has
received fees for speaking from Napp, AstraZeneca, BI and Pfizer. None of these conflicts of interest are related to the work of this
review and are unrelated to the topic of the review.
T Donovan: none known.
L Felix: none known.
A Mathioudakis: none known.
S Milan: none known.
S Spencer: named co-investigator on a study conducted to develop a series of reviews on bronchiectasis.
S O U R C E S O F S U P P O R T
Internal sources
• Edge Hill University, UK.
Funded Lambert Felix to provide support for a series of reviews on bronchiectasis.
External sources
• National Institute of Health Research, UK.
AGM was funded by an NIHR Academic Clinical Fellowship in Respiratory Medicine
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
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